Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 17, 2007, Pages 3053-3059

  George, Jacob ^a   Struthers, Allan D ^b  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Aldosterone; Eplerenone; Heart failure; Hypertension

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; KETOCONAZOLE; LOSARTAN; SPIRONOLACTONE;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DOSE TIME EFFECT RELATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEART FAILURE; HORMONE ACTION; HORMONE INHIBITION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; LIVER FAILURE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; STEROID METABOLISM; STRUCTURE ACTIVITY RELATION; SYSTOLIC DYSFUNCTION; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ALDOSTERONE ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR AGENTS; DRUG AND NARCOTIC CONTROL; HEART FAILURE; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 37349099095     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.17.3053     Document Type: Review

References (52)

1. MCMAHON EG: Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. (2001) 1(2):190-196.
2. SIMPSON SA, TAIT JF, WETTSTEIN A, NEHER R, VON EUW J, REICHSTEIN T: Isolierung eines neuen kristallisierten Hormons aus Nebennieren mit besonders hoher Wirksamkeit auf den Mineralstoffwechsel. Experientia (1953) 9:333-335.
3. NISHIKAWA T, SUEMATSU S, SAITO J et al.: Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J. Steroid Biochem. Mol. Biol. (2005) 96(3-4):309-316.
4. SWEDBERG K, ENEROTH P, KJEKSHUS J, WILHELMSEN L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group. Circulation (1990) 82(5):1730-1736.
5. STAESSEN J, LIJNEN P, FAGARD R, VERSCHUEREN LJ, AMERY A: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol. (1981) 91(3):457-465.
6. STRUTHERS AD: Aldosterone blockade in cardiovascular disease. Heart (2004) 90(10):1229-1234.
7. SHARMAN D, MORRIS A, STRUTHERS A: Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes meilitus. Diabetologia (2007) 50(10):2061-2066.
8. MCKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation (1999) 100(10):1056-1064.
9. TAKEDA Y, MIYAMORI I, YONEDA T et al.: Production of aldosterone in isolated rat blood vessels. Hypertension (1995) 25(2):170-173.
10. SILVESTRE JS, ROBERT V, HEYMES C et al.: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. (1998) 273(9):4883-4891.
11. CHAI W, DANSER AH: Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch. Pharmacol. (2006) 374(3):153-162.
12. 2+, and H2O2 in peripheral blood mononuclear cells. Circulation (2005) 111(1):51-57.
13. ROCHA R, STIER CT Jr, KIFOR I et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology (2000) 141(10):3871-3878.
14. OBERLEITHNER H, RIETHMULLER C, LUDWIG T, HAUSBERG M, SCHILLERS H: Aldosterone remodels human endothelium. Acta Physiol. (Oxf) (2006) 187(1-2):305-312.
15. HILLEBRAND U, SCHILLERS H, RIETHMULLER C et al.: Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J. Hypertens. (2007) 25(3):639-647.
16. CELIK T, IYISOY A, KURSAKLIOGLU H, ISIK E: Eplerenone suppresses neointima after coronary stenting in pigs: could it be extrapolated to stent restenosis in humans? Int. J. Cardiol. (2007) 115(1):97-98.
17. WAKABAYASHI K, SUZUKI H, SATO T et al.: Eplerenone suppresses neointimal formation after coronary stent implantation in swine, Int. J. Cardiol. (2006) 107(2):260-266.
18. FARQUHARSON CA, STRUTHERS AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation (2000) 101(6):594-597.
19. BARR CS, LANG CC, HANSON J et al.: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. (1995) 76(17):1259-1265.
20. MACDONALD JE, KENNEDY N, STRUTHERS AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart (2004) 90(7):765-770.
21. MACFADYEN RJ, BARR CS, STRUTHERS AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc. Res. (1997) 35(1):30-34.
22. LOSKUTOFF DJ, QUIGLEY JP: PAI-1, fibrosis, and the elusive provisional fibrin matrix. J. Clin. Invest. (2000) 106(12):1441-1443.
23. MENARD J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol. Cell. Endocrinol. (2004) 217(1-2):45-52.
24. COOK CS, BERRY LM, KIM DH et al.: Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab. Dispos. (2002) 30(12):1344-1351.
25. DELYANI JA: Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. (2000) 57(4):1408-1411.
26. WHITE WB, DUPREZ D, ST HILLAIRE R et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension (2003) 41(5):1021-1026.
27. BROWN NJ: Eplerenone: cardiovascular protection. Circulation (2003) 107(19):2512-2518.
28. FDA USFDA: INSPRA™ (eplerenone tablets) - FDA label (2002).
29. WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15(8):709-716.
30. DELYANI J, MYLES K, FUNDER J: Eplerenone (SC 66110) a highly selective aldosterone antagonist. Am J. Hypertens. (1998) 11:A94.
31. FLACK JM, OPARIL S, PRATT JH et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. (2003) 41(7):1148-1155.
32. KRUM H, NOLLY H, WORKMAN D et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2002) 40(2):117-123.
33. BRILLA CG, MATSUBARA LS, WEBER KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell Cardiol. (1993) 25(5):563-575.
34. LACOLLEY P, LABAT C, PUJOL A et al.: Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation (2002) 106(22):2848-2853.
35. SCHAFER A, FRACCAROLLO D, HILDEMANN SK et al.: Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc. Res. (2003) 58(3):655-662.
36. FRACCAROLLO D, GALUPPO P, HILDEMANN S et al.: Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J. Am. Coll. Cardiol. (2003) 42(9):1666-1673.
37. SUSIC D, VARAGIC J, AHN J, MATAVELLI L, FROHLICH ED: Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am. J. Physiol. Heart Circ. Physiol. (2007) 292(1):H175-H179.
38. SUZUKI G, MORITA H, MISHIMA T et al.: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation (2002) 106(23):2967-2972.
39. SHROFF SC, RYU K, MARTOVITZ NL, HOIT BD, STAMBLER BS: Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. (2006) 17(5):534-541.
40. EPSTEIN M AJ, RONIKER B: Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. Hypertension (1999) 33:1075.
41. CROOM KF, PERRY CM: Eplerenone: a review of its use in essential hypertension. Am. J. Cardiovasc. Drugs (2005) 5(1):51-69.
42. PITT B, REICHEK N, WILLENBROCK R et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108(15):1831-1838.
43. PRISANT LM, KRUM H, RONIKER B et al.: Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J. Clin. Pharmacol. (2003) 43(11):1203-1210.
44. NISHIZAKA MK, ZAMAN MA, CALHOUN DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. (2003) 16(11):925-930.
45. PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348(14):1309-1321.
46. PITT B, GHEORGHIADE M, ZANNAD F et al.: Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction
47. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am. J. Cardiol. (1996) 78(8):902-907.
48. JUURLINK DN, MAMDANI MM, LEE DS et al.: Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N. Engl. J. Med. (2004) 351(6):543-551.
49. PITT B, FERRARI R, GHEORGHIADE M et al.: Aldosterone blockade in post-acute myocardial infarction heart failure. Clin. Cardiol. (2006) 29(10):434-438.
50. MCMURRAY JJ, O'MEARA E: Treatment of heart failure with spironolactone-trial and tribulations. N. Engl. J. Med. (2004) 351(6):526-528.
51. EPSTEIN M, WILLIAMS GH, WEINBERGER M et al.: Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. In: (2006):940-951.
52. GOSSE P, MACFADYEN RJ: Does eplerenone have a future in the management of hypertension in Europe? J. Hum. Hypertens. (2006) 20(11):829-832.